Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 705 of 1290 results for position

  1. Stage 4: treatment, assessment and monitoring

    In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.

  2. Content assurance service

    Our content assurance service. Includes what the service offers, how to apply and pricing.

  3. Consultations

    People can comment on our guidance at specific stages in its development.

  4. Consultations

    People can comment on our guidance at specific stages in its development.

  5. Appraisal methodology for records 1999-2013

    Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.

  6. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

  7. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  8. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

    Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

  9. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

    Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.

  10. Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA718)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.

  11. Alcohol interventions in secondary and further education (NG135)

    This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

  12. Key question: effective

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  13. Website feedback

    .org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/","name":"Home"}}]} Website feedback...